ArticleJournal of asthma and allergy2026
Expression of miR-185-5p, miR-146b-5p, miR-320b, and miR-21-5p in Eosinophil Subtypes in Allergic Asthma Patients.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic asthma (AA) is a common type 2 eosinophilic asthma phenotype. Inflammatory (iEOS) and lung-resident (rEOS) eosinophil subtypes may contribute to its underlying inflammatory processes. The biological functions of these eosinophils are tightly regulated by gene expression, with micro ribonucleic acids (miRNAs) emerging as key modulators and potential biomarkers. Purpose: To investigate the expression of miR-185-5p, miR-146b-5p, miR-320b, and miR-21-5p in eosinophil subtypes and relate with their plasma levels in AA patients. Patients and Methods: The study included 13 AA patients and 16 healthy subjects (HS). All AA patients underwent bronchial allergen challenge (BAC) with Results: Before BAC, miR-185-5p and miR-146b-5p expression were elevated in both eosinophil subtypes relative to HS, with miR-185-5p showing higher expression in iEOS-like cells than in rEOS-like cells within the AA group. miR-320b was elevated only in iEOS-like cells relative to HS and remained higher than in rEOS-like cells within the AA group, whereas miR-21-5p was decreased only in iEOS-like cells and remained lower than in rEOS-like cells. After BAC, miR-146b-5p expression decreased in iEOS-like cells but increased in rEOS-like cells. Plasma analysis revealed elevated levels of all investigated miRNAs in AA patients relative to HS before BAC. However, after BAC, miR-185-5p and miR-146b-5p remained elevated, whereas miR-320b and miR-21-5p decreased to levels not significantly different from HS. Conclusion: Elevated miR-185-5p and miR-320b expression in iEOS-like cells compared to rEOS-like cells from AA patients highlights differences in their biological properties. Following the BAC, miR-146b-5p expression decreased in iEOS-like cells but increased in rEOS-like cells. Moreover, miR-185-5p and miR-146b-5p remained elevated in plasma, suggesting their potential to reflect chronic inflammation rather than acute response to allergen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.